Phase I Dose Escalation Clinical Trial of Adenovirus Vector Carrying Osteocalcin Promoter-Driven Herpes Simplex Virus Thymidine Kinase in Localized and Metastatic Hormone-Refractory Prostate Cancer
Hiroyuki Kubo(Emory University), Leland W.K. Chung(VA Palo Alto Health Care System), Yoshitaka Wada(University of Virginia), Thomas A. Gardner(Indiana University), Masayuki Nakagawa(Japan Meteorological Agency), Jay Y. Gillenwater(University of Virginia), Kenneth S. Koeneman(University of Virginia Health System), Shigeji Matsubara(University of Virginia), Ling Yang(Chengdu Medical College), Akinobu Gotoh(Nissin Kogyo (Japan)), Hua Yang(Sichuan Academy of Forestry), Margaret E. Black(Washington State University), Haiyen E. Zhau(Cedars-Sinai Medical Center), Chinghai Kao(University of Virginia), So Dug Lim(Emory University)
Cited by 127
Related Papers
Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer.
|PubMed|1994|739
Highly Efficient Capture of Circulating Tumor Cells by Using Nanostructured Silicon Substrates with Integrated Chaotic Micromixers
|Angewandte Chemie International Edition|2011|618
Bioconjugated quantum dots for multiplexed and quantitative immunohistochemistry
|Nature Protocols|2007|520
A mutant herpes simplex virus type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography
|Proceedings of the National Academy of Sciences|2000|458